{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:45:03Z","timestamp":1790675103213,"version":"4.1.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T00:00:00Z","timestamp":1629676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10787-021-00863-2","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T14:06:06Z","timestamp":1629727566000},"page":"1291-1306","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases"],"prefix":"10.1007","volume":"29","author":[{"given":"Naeemeh","family":"Khalesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahla","family":"Korani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitra","family":"Korani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas P.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8656-1444","authenticated-orcid":false,"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,23]]},"reference":[{"issue":"6","key":"863_CR1","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","volume":"28","author":"J Adams","year":"2001","unstructured":"Adams J (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28(6):613\u2013619","journal-title":"Semin Oncol"},{"issue":"6","key":"863_CR2","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1097\/00001622-200211000-00007","volume":"14","author":"J Adams","year":"2002","unstructured":"Adams J (2002a) Proteasome inhibitors as new anticancer drugs. Curr Opin Oncol 14(6):628\u2013634","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"863_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1634\/theoncologist.7-1-9","volume":"7","author":"J Adams","year":"2002","unstructured":"Adams J (2002b) Development of the proteasome inhibitor PS-341. Oncologist 7(1):9\u201316","journal-title":"Oncologist"},{"issue":"5","key":"863_CR4","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrc1361","volume":"4","author":"J Adams","year":"2004","unstructured":"Adams J (2004) The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4(5):349\u2013360","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"863_CR5","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al (1999) Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59(11):2615\u20132622","journal-title":"Cancer Res"},{"issue":"5","key":"863_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1046\/j.1523-1755.1999.00728.x","volume":"56","author":"M Al-Douahji","year":"1999","unstructured":"Al-Douahji M, Brugarolas J, Brown PA, Stehman-Breen CO, Alpers CE, Shankland SJ (1999) The cyclin kinase inhibitor p21WAF1\/CIP1 is required for glomerular hypertrophy in experimental diabetic nephropathy. Kidney Int 56(5):1691\u20131699","journal-title":"Kidney Int"},{"issue":"7","key":"863_CR7","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","volume":"74","author":"T Alexander","year":"2015","unstructured":"Alexander T, Sarfert R, Klotsche J, K\u00fchl AA, Rubbert-Roth A, Lorenz H-M et al (2015) The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus. Ann Rheum Dis 74(7):1474\u20131478","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"863_CR8","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1002\/eji.201847492","volume":"48","author":"T Alexander","year":"2018","unstructured":"Alexander T, Cheng Q, Klotsche J, Khodadadi L, Waka A, Biesen R et al (2018) Proteasome inhibition with bortezomib induces a therapeutically relevant depletion of plasma cells in SLE but does not target their precursors. Eur J Immunol 48(9):1573\u20131579","journal-title":"Eur J Immunol"},{"issue":"12","key":"863_CR9","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1038\/sj.cdd.4400436","volume":"5","author":"B An","year":"1998","unstructured":"An B, Goldfarb RH, Siman R, Dou QP (1998) Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 5(12):1062\u20131075","journal-title":"Cell Death Differ"},{"issue":"11","key":"863_CR10","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s10067-013-2330-3","volume":"32","author":"S Andrejevic","year":"2013","unstructured":"Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci-Nikolic B (2013) Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity. Clin Rheumatol 32(11):1619\u20131626","journal-title":"Clin Rheumatol"},{"issue":"4 Suppl 92","key":"863_CR11","first-page":"S74","volume":"33","author":"M Basler","year":"2015","unstructured":"Basler M, Mundt S, Bitzer A, Schmidt C, Groettrup M (2015) The immunoproteasome: a novel drug target for autoimmune diseases. Clin Exp Rheumatol 33(4 Suppl 92):S74\u2013S79","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"863_CR12","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/nm924","volume":"9","author":"M Belghith","year":"2003","unstructured":"Belghith M, Bluestone JA, Barriot S, M\u00e9gret J, Bach J-F, Chatenoud L (2003) TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9(9):1202\u20131208","journal-title":"Nat Med"},{"issue":"1","key":"863_CR13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3390\/cells9010077","volume":"9","author":"D Benfaremo","year":"2019","unstructured":"Benfaremo D, Gabrielli A (2019) Is there a future for anti-CD38 antibody therapy in systemic autoimmune diseases? Cells 9(1):77","journal-title":"Cells"},{"key":"863_CR14","first-page":"915","volume":"115","author":"KR Carson","year":"2010","unstructured":"Carson KR, Beckwith LG, Mehta J (2010) Successful treatment of IgM-mediated autoimmune hemolytic anemia with bortezomib. Blood (united States) 115:915","journal-title":"Blood (united States)"},{"issue":"6","key":"863_CR15","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.4049\/jimmunol.158.6.2947","volume":"158","author":"L Chatenoud","year":"1997","unstructured":"Chatenoud L, Primo J, Bach JF (1997) CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 158(6):2947\u20132954","journal-title":"J Immunol"},{"issue":"8","key":"863_CR16","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1021\/acscentsci.7b00252","volume":"3","author":"PM Cromm","year":"2017","unstructured":"Cromm PM, Crews CM (2017) The proteasome in modern drug discovery: second life of a highly valuable drug target. ACS Cent Sci 3(8):830\u2013838","journal-title":"ACS Cent Sci"},{"key":"863_CR17","first-page":"289","volume":"83","author":"G D\u2019Amico","year":"1999","unstructured":"D\u2019Amico G (1999) Tubulointerstitium as predictor of progression of glomerular diseases. Nephron (switzerland) 83:289\u2013295","journal-title":"Nephron (switzerland)"},{"issue":"5","key":"863_CR18","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJM200108023450506","volume":"345","author":"A Davidson","year":"2001","unstructured":"Davidson A, Diamond B (2001) Autoimmune diseases. N Engl J Med 345(5):340\u2013350","journal-title":"N Engl J Med"},{"issue":"7","key":"863_CR19","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/s41590-018-0120-4","volume":"19","author":"M Dominguez-Villar","year":"2018","unstructured":"Dominguez-Villar M, Hafler DA (2018) Regulatory T cells in autoimmune disease. Nat Immunol 19(7):665\u2013673","journal-title":"Nat Immunol"},{"issue":"4","key":"863_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s00109-003-0422-2","volume":"81","author":"PJ Elliott","year":"2003","unstructured":"Elliott PJ, Zollner TM, Boehncke W-H (2003) Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med (berl) 81(4):235\u2013245","journal-title":"J Mol Med (berl)"},{"issue":"1","key":"863_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.transproceed.2008.10.073","volume":"41","author":"MJ Everly","year":"2009","unstructured":"Everly MJ, Everly JJ, Susskind B, Brailey P, Arend LJ, Alloway RR et al (2009) Proteasome inhibition reduces donor-specific antibody levels. Transplant Proc 41(1):105\u2013107","journal-title":"Transplant Proc"},{"issue":"13","key":"863_CR22","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.2174\/138945012803530053","volume":"13","author":"A Fierabracci","year":"2012","unstructured":"Fierabracci A (2012) Proteasome inhibitors: a new perspective for treating autoimmune diseases. Curr Drug Targets 13(13):1665\u20131675","journal-title":"Curr Drug Targets"},{"issue":"1","key":"863_CR23","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Prim [internet] 4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Prim [internet]"},{"issue":"9","key":"863_CR24","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1002\/eji.200838413","volume":"38","author":"N Fissolo","year":"2008","unstructured":"Fissolo N, Kraus M, Reich M, Ayturan M, Overkleeft H, Driessen C et al (2008) Dual inhibition of proteasomal and lysosomal proteolysis ameliorates autoimmune central nervous system inflammation. Eur J Immunol [internet] 38(9):2401\u20132411. https:\/\/doi.org\/10.1002\/eji.200838413","journal-title":"Eur J Immunol [internet]"},{"issue":"9482","key":"863_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0140-6736(05)66990-5","volume":"366","author":"RI Fox","year":"2005","unstructured":"Fox RI (2005) Sj\u00f6gren\u2019s syndrome. Lancet (London, England) 366(9482):321\u2013331","journal-title":"Lancet (london, England)"},{"key":"863_CR26","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/ard.2010.133256","volume":"70","author":"K Fr\u00f6hlich","year":"2011","unstructured":"Fr\u00f6hlich K, Holle JU, Aries PM, Gross WL, Moosig F (2011) Successful use of bortezomib in a patient with systemic lupus erythematosus and multiple myeloma. Ann Rheum Dis (england) 70:1344\u20131345","journal-title":"Ann Rheum Dis (england)"},{"issue":"22","key":"863_CR27","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1056\/NEJM199811263392202","volume":"339","author":"M Furlan","year":"1998","unstructured":"Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B et al (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 339(22):1578\u20131584","journal-title":"N Engl J Med"},{"issue":"6","key":"863_CR28","doi-asserted-by":"publisher","first-page":"406","DOI":"10.7326\/0003-4819-146-6-200703200-00005","volume":"146","author":"YPM Goekoop-Ruiterman","year":"2007","unstructured":"Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJSM, Hazes JMW et al (2007) Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 146(6):406\u2013415","journal-title":"Ann Intern Med"},{"issue":"Pt 1","key":"863_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1042\/BST0350012","volume":"35","author":"AL Goldberg","year":"2007","unstructured":"Goldberg AL (2007) Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35(Pt 1):12\u201317","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"863_CR30","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.4049\/jimmunol.1002539","volume":"186","author":"AM Gomez","year":"2011","unstructured":"Gomez AM, Vrolix K, Mart\u00ednez-Mart\u00ednez P, Molenaar PC, Phernambucq M, van der Esch E et al (2011) Proteasome inhibition with bortezomib depletes plasma cells and autoantibodies in experimental autoimmune myasthenia gravis. J Immunol 186(4):2503\u20132513","journal-title":"J Immunol"},{"key":"863_CR31","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1749-6632.2012.06824.x","volume":"1274","author":"AM Gomez","year":"2012","unstructured":"Gomez AM, Willcox N, Molenaar PC, Buurman W, Martinez-Martinez P, De Baets MH et al (2012) Targeting plasma cells with proteasome inhibitors: possible roles in treating myasthenia gravis? Ann N Y Acad Sci 1274:48\u201359","journal-title":"Ann N Y Acad Sci"},{"issue":"3","key":"863_CR32","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.4049\/jimmunol.1301555","volume":"193","author":"AM Gomez","year":"2014","unstructured":"Gomez AM, Willcox N, Vrolix K, Hummel J, Nogales-Gadea G, Saxena A et al (2014) Proteasome inhibition with bortezomib depletes plasma cells and specific autoantibody production in primary thymic cell cultures from early-onset myasthenia gravis patients. J Immunol 193(3):1055\u20131063","journal-title":"J Immunol"},{"issue":"3","key":"863_CR33","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41433-020-01334-8","volume":"35","author":"SM Gospe","year":"2021","unstructured":"Gospe SM, Chen JJ, Bhatti MT (2021) Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment. Eye [internet] 35(3):753\u2013768. https:\/\/doi.org\/10.1038\/s41433-020-01334-8","journal-title":"Eye [internet]"},{"key":"863_CR34","doi-asserted-by":"crossref","unstructured":"Gregson A, Thompson K, Tsirka SE, Selwood DL (2019) Emerging small-molecule treatments for multiple sclerosis: focus on B cells. F1000Research [Internet] 8:F1000 Faculty Rev-245. https:\/\/pubmed.ncbi.nlm.nih.gov\/30863536. Accessed 17 Aug 2021","DOI":"10.12688\/f1000research.16495.1"},{"key":"863_CR35","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nri2687","volume":"10","author":"M Groettrup","year":"2010","unstructured":"Groettrup M, Kirk CJ, Basler M (2010) Proteasomes in immune cells: more than peptide producers? Nat Rev Immunol Engl 10:73\u201378","journal-title":"Nat Rev Immunol Engl"},{"key":"863_CR36","doi-asserted-by":"publisher","first-page":"7247238","DOI":"10.1155\/2019\/7247238","volume":"2019","author":"Q Guan","year":"2019","unstructured":"Guan Q (2019) A comprehensive review and update on the pathogenesis of inflammatory Bowel disease. J Immunol Res 2019:7247238","journal-title":"J Immunol Res"},{"issue":"2","key":"863_CR37","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1159\/000334955","volume":"120","author":"N Hainz","year":"2012","unstructured":"Hainz N, Thomas S, Neubert K, Meister S, Benz K, Rauh M et al (2012) The proteasome inhibitor bortezomib prevents lupus nephritis in the NZB\/W F1 mouse model by preservation of glomerular and tubulointerstitial architecture. Nephron Exp Nephrol 120(2):e47-58","journal-title":"Nephron Exp Nephrol"},{"issue":"5666","key":"863_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/274065a0","volume":"274","author":"S Heinemann","year":"1978","unstructured":"Heinemann S, Merlie J, Lindstrom J (1978) Modulation of acetylcholine receptor in rat diaphragm by anti-receptor sera. Nature 274(5666):65\u201368","journal-title":"Nature"},{"issue":"3","key":"863_CR39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe F, D\u00f6rner T, Hauser AE, Hoyer BF, Mei H, Radbruch A (2011) Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat Rev Rheumatol 7(3):170\u2013178","journal-title":"Nat Rev Rheumatol"},{"key":"863_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jneuroim.2008.06.027","volume":"201\u2013202","author":"ME Hill","year":"2008","unstructured":"Hill ME, Shiono H, Newsom-Davis J, Willcox N (2008) The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics. J Neuroimmunol 201\u2013202:50\u201356","journal-title":"J Neuroimmunol"},{"issue":"2","key":"863_CR41","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1182\/blood-2010-05-284737","volume":"117","author":"M Hirai","year":"2011","unstructured":"Hirai M, Kadowaki N, Kitawaki T, Fujita H, Takaori-Kondo A, Fukui R et al (2011) Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis. Blood 117(2):500\u2013509","journal-title":"Blood"},{"key":"863_CR42","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","volume":"9","author":"K Hofmann","year":"2018","unstructured":"Hofmann K, Clauder A-K, Manz RA (2018) Targeting B cells and plasma cells in autoimmune diseases. Front Immunol 9:835","journal-title":"Front Immunol"},{"issue":"35","key":"863_CR43","doi-asserted-by":"publisher","first-page":"8708","DOI":"10.1002\/anie.201201616","volume":"51","author":"EM Huber","year":"2012","unstructured":"Huber EM, Groll M (2012) Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development. Angew Chem Int Ed Engl 51(35):8708\u20138720","journal-title":"Angew Chem Int Ed Engl"},{"issue":"2","key":"863_CR44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/art.33333","volume":"64","author":"HT Ichikawa","year":"2012","unstructured":"Ichikawa HT, Conley T, Muchamuel T, Jiang J, Lee S, Owen T et al (2012) Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheumatol 64(2):493\u2013503","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"863_CR45","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41590-018-0129-8","volume":"19","author":"JRJ Inshaw","year":"2018","unstructured":"Inshaw JRJ, Cutler AJ, Burren OS, Stefana MI, Todd JA (2018) Approaches and advances in the genetic causes of autoimmune disease and their implications. Nat Immunol 19(7):674\u2013684","journal-title":"Nat Immunol"},{"issue":"10","key":"863_CR46","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1016\/j.bbmt.2014.06.032","volume":"20","author":"P Khandelwal","year":"2014","unstructured":"Khandelwal P, Davies SM, Grimley MS, Jordan MB, Curtis BR, Jodele S et al (2014) Bortezomib for refractory autoimmunity in pediatrics. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20(10):1654\u20131659","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"issue":"8","key":"863_CR47","doi-asserted-by":"publisher","first-page":"e0135081","DOI":"10.1371\/journal.pone.0135081","volume":"10","author":"L Khodadadi","year":"2015","unstructured":"Khodadadi L, Cheng Q, Alexander T, Sercan-Alp \u00d6, Klotsche J, Radbruch A et al (2015) Bortezomib plus continuous B cell depletion results in sustained plasma cell depletion and amelioration of lupus nephritis in NZB\/W F1 mice. PLoS ONE 10(8):e0135081","journal-title":"PLoS ONE"},{"issue":"2","key":"863_CR48","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/ni.2203","volume":"13","author":"EZ Kincaid","year":"2011","unstructured":"Kincaid EZ, Che JW, York I, Escobar H, Reyes-Vargas E, Delgado JC et al (2011) Mice completely lacking immunoproteasomes show major changes in antigen presentation. Nat Immunol 13(2):129\u2013135","journal-title":"Nat Immunol"},{"issue":"7","key":"863_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/ni1090","volume":"5","author":"PM Kloetzel","year":"2004","unstructured":"Kloetzel PM (2004) Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII. Nat Immunol 5(7):661\u20139","journal-title":"Nat Immunol"},{"key":"863_CR198","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S1474-4422(16)00033-8","volume":"15","author":"S Kohler","year":"2016","unstructured":"Kohler S, Losen M, Alexander T, Hiepe F, Meisel A (2016) Myasthenia gravis: subgroup classifications. Lancet Neurol (england) 15:356\u2013357","journal-title":"Lancet Neurol (england)"},{"issue":"1","key":"863_CR199","doi-asserted-by":"publisher","first-page":"e024523","DOI":"10.1136\/bmjopen-2018-024523","volume":"9","author":"S Kohler","year":"2019","unstructured":"Kohler S, M\u00e4rschenz S, Grittner U, Alexander T, Hiepe F, Meisel A (2019) Bortezomib in antibody-mediated autoimmune diseases (TAVAB): study protocol for a unicentric, non-randomised, non-placebo controlled trial. BMJ Open 9(1):e024523","journal-title":"BMJ Open"},{"issue":"13","key":"863_CR51","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1056\/NEJMra041347","volume":"352","author":"H K\u00f6ller","year":"2005","unstructured":"K\u00f6ller H, Kieseier BC, Jander S, Hartung H-P (2005) Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352(13):1343\u20131356","journal-title":"N Engl J Med"},{"issue":"3","key":"863_CR52","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jbspin.2019.01.019","volume":"86","author":"S Lassoued","year":"2019","unstructured":"Lassoued S, Moyano C, Beldjerd M, Pauly P, Lassoued D, Billey T (2019) Bortezomib improved the joint manifestations of rheumatoid arthritis in three patients. Jt Bone Spine 86(3):381\u2013382","journal-title":"Jt Bone Spine"},{"issue":"11","key":"863_CR53","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1136\/ard.2008.097709","volume":"68","author":"S-W Lee","year":"2009","unstructured":"Lee S-W, Kim J-H, Park Y-B, Lee S-K (2009) Bortezomib attenuates murine collagen-induced arthritis. Ann Rheum Dis 68(11):1761\u20131767","journal-title":"Ann Rheum Dis"},{"key":"863_CR180","doi-asserted-by":"crossref","unstructured":"Lin X, Rui K, Deng J, Tian J, Wang X, Wang S et al (2015) Th17 cells play a critical role in the development of experimental Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 74(6):1302\u20131310","DOI":"10.1136\/annrheumdis-2013-204584"},{"issue":"5","key":"863_CR50","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/path.2511","volume":"217","author":"Y Liu","year":"2009","unstructured":"Liu Y, Wu J, Wu H, Wang T, Gan H, Zhang X et al (2009) UCH-L1 expression of podocytes in diseased glomeruli and in vitro. J Pathol 217(5):642\u2013653","journal-title":"J Pathol"},{"issue":"52","key":"863_CR54","doi-asserted-by":"publisher","first-page":"e5760","DOI":"10.1097\/MD.0000000000005760","volume":"95","author":"J Liu","year":"2016","unstructured":"Liu J, Li J, Chen M, Kuang L (2016) Bortezomib followed by autologous stem cell transplantation in a patient with rheumatoid arthritis: a case report and review of the literature. Medicine (Baltimore) 95(52):e5760","journal-title":"Medicine (baltimore)"},{"issue":"2","key":"863_CR55","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/00007890-200107270-00005","volume":"72","author":"H Luo","year":"2001","unstructured":"Luo H, Wu Y, Qi S, Wan X, Chen H, Wu J (2001) A proteasome inhibitor effectively prevents mouse heart allograft rejection. Transplantation 72(2):196\u2013202","journal-title":"Transplantation"},{"issue":"1","key":"863_CR56","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1177\/0961203310379871","volume":"20","author":"A Matrat","year":"2011","unstructured":"Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, Bienvenu J et al (2011) Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 20(1):28\u201334","journal-title":"Lupus"},{"key":"863_CR57","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1111\/bjh.12696","volume":"164","author":"MA Mazepa","year":"2014","unstructured":"Mazepa MA, Raval JS, Moll S, Ma A, Park YA (2014) Bortezomib induces clinical remission and reduction of ADAMTS13 inhibitory antibodies in relapsed refractory idiopathic thrombotic thrombocytopenic purpura. Br J Haematol (england) 164:900\u2013902","journal-title":"Br J Haematol (england)"},{"issue":"23","key":"863_CR58","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"IB McInnes","year":"2011","unstructured":"McInnes IB, Schett G (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365(23):2205\u20132219","journal-title":"N Engl J Med"},{"issue":"11","key":"863_CR59","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/blood-2014-02-555169","volume":"125","author":"HE Mei","year":"2015","unstructured":"Mei HE, Wirries I, Fr\u00f6lich D, Brisslert M, Giesecke C, Gr\u00fcn JR et al (2015) A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. Blood 125(11):1739\u20131748","journal-title":"Blood"},{"key":"863_CR60","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3389\/fimmu.2017.00428","volume":"8","author":"G Mondanelli","year":"2017","unstructured":"Mondanelli G, Albini E, Pallotta MT, Volpi C, Chatenoud L, Kuhn C et al (2017) The proteasome inhibitor bortezomib controls indoleamine 2,3-dioxygenase 1 breakdown and restores immune regulation in autoimmune diabetes. Front Immunol 8:428","journal-title":"Front Immunol"},{"issue":"3","key":"863_CR61","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1053\/j.seminhematol.2012.04.004","volume":"49","author":"E Moran","year":"2012","unstructured":"Moran E, Carbone F, Augusti V, Patrone F, Ballestrero A, Nencioni A (2012) Proteasome inhibitors as immunosuppressants: biological rationale and clinical experience. Semin Hematol 49(3):270\u2013276","journal-title":"Semin Hematol"},{"key":"863_CR62","doi-asserted-by":"crossref","first-page":"175628642199963","DOI":"10.1177\/1756286421999631","volume":"14","author":"J Motte","year":"2021","unstructured":"Motte J, Fisse AL, K\u00f6se N, Gr\u00fcter T, Mork H, Athanasopoulos D et al (2021) Treatment response to cyclophosphamide, rituximab, and bortezomib in chronic immune-mediated sensorimotor neuropathies: a retrospective cohort study. Ther Adv Neurol Disord [internet] 14:1756286421999631\u20131756286421999631","journal-title":"Ther Adv Neurol Disord [internet]"},{"issue":"7","key":"863_CR63","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nm.1978","volume":"15","author":"T Muchamuel","year":"2009","unstructured":"Muchamuel T, Basler M, Aujay MA, Suzuki E, Kalim KW, Lauer C et al (2009) A selective inhibitor of the immunoproteasome subunit LMP7 blocks cytokine production and attenuates progression of experimental arthritis. Nat Med 15(7):781\u2013787","journal-title":"Nat Med"},{"issue":"7","key":"863_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/nrd2056","volume":"5","author":"G Nalepa","year":"2006","unstructured":"Nalepa G, Rolfe M, Harper JW (2006) Drug discovery in the ubiquitin\u2013proteasome system. Nat Rev Drug Discov 5(7):596\u2013613","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"863_CR65","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/eji.200535298","volume":"36","author":"A Nencioni","year":"2006","unstructured":"Nencioni A, Garuti A, Schwarzenberg K, Cirmena G, Dal Bello G, Rocco I et al (2006) Proteasome inhibitor-induced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 36(3):681\u2013689","journal-title":"Eur J Immunol"},{"issue":"7","key":"863_CR66","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/nm1763","volume":"14","author":"K Neubert","year":"2008","unstructured":"Neubert K, Meister S, Moser K, Weisel F, Maseda D, Amann K et al (2008) The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 14(7):748\u2013755","journal-title":"Nat Med"},{"key":"863_CR67","first-page":"814748","volume":"2015","author":"RC Oliveira","year":"2015","unstructured":"Oliveira RC, Oliveira IS, Santiago MB, Sousa Atta MLB, Atta AM (2015) High avidity dsDNA autoantibodies in Brazilian women with systemic lupus erythematosus: correlation with active disease and renal dysfunction. J Immunol Res 2015:814748","journal-title":"J Immunol Res"},{"issue":"9","key":"863_CR68","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1038\/ni.2077","volume":"12","author":"MT Pallotta","year":"2011","unstructured":"Pallotta MT, Orabona C, Volpi C, Vacca C, Belladonna ML, Bianchi R et al (2011) Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol 12(9):870\u2013878","journal-title":"Nat Immunol"},{"issue":"26","key":"863_CR69","doi-asserted-by":"publisher","first-page":"15671","DOI":"10.1073\/pnas.95.26.15671","volume":"95","author":"VJ Palombella","year":"1998","unstructured":"Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS et al (1998) Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 95(26):15671\u201315676","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"863_CR70","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1111\/bjh.13993","volume":"173","author":"CJ Patriquin","year":"2016","unstructured":"Patriquin CJ, Thomas MR, Dutt T, McGuckin S, Blombery PA, Cranfield T et al (2016) Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura. Br J Haematol 173(5):779\u2013785","journal-title":"Br J Haematol"},{"issue":"11\u201312","key":"863_CR71","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/bies.20852","volume":"30","author":"S Paul","year":"2008","unstructured":"Paul S (2008) Dysfunction of the ubiquitin-proteasome system in multiple disease conditions: therapeutic approaches. BioEssays 30(11\u201312):1172\u20131184","journal-title":"BioEssays"},{"issue":"9","key":"863_CR72","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1007\/s00415-017-8599-4","volume":"264","author":"K Pitarokoili","year":"2017","unstructured":"Pitarokoili K, Yoon M-S, Kr\u00f6ger I, Reinacher-Schick A, Gold R, Schneider-Gold C (2017) Severe refractory CIDP: a case series of 10 patients treated with bortezomib. J Neurol [internet] 264(9):2010\u20132020","journal-title":"J Neurol [internet]"},{"issue":"3","key":"863_CR73","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/art.30177","volume":"63","author":"K Polzer","year":"2011","unstructured":"Polzer K, Neubert K, Meister S, Frey B, Baum W, Distler JH et al (2011) Proteasome inhibition aggravates tumor necrosis factor-mediated bone resorption in a mouse model of inflammatory arthritis. Arthritis Rheumatol 63(3):670\u2013680","journal-title":"Arthritis Rheumatol"},{"key":"863_CR74","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1476-511X-10-177","volume":"10","author":"AA Qureshi","year":"2011","unstructured":"Qureshi AA, Tan X, Reis JC, Badr MZ, Papasian CJ, Morrison DC et al (2011) Suppression of nitric oxide induction and pro-inflammatory cytokines by novel proteasome inhibitors in various experimental models. Lipids Health Dis 10:177","journal-title":"Lipids Health Dis"},{"issue":"1","key":"863_CR75","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/bloodadvances.2016001412","volume":"1","author":"S Ratnasingam","year":"2016","unstructured":"Ratnasingam S, Walker PA, Tran H, Kaplan ZS, McFadyen JD, Tran H et al (2016) Bortezomib-based antibody depletion for refractory autoimmune hematological diseases. Blood Adv 1(1):31\u201335","journal-title":"Blood Adv"},{"issue":"24","key":"863_CR76","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352(24):2487\u20132498","journal-title":"N Engl J Med"},{"issue":"2","key":"863_CR77","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/00005072-198003000-00005","volume":"39","author":"K Sahashi","year":"1980","unstructured":"Sahashi K, Engel AG, Lambert EH, Howard FMJ (1980) Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis. J Neuropathol Exp Neurol 39(2):160\u2013172","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"863_CR78","first-page":"167","volume":"16","author":"D Schlafer","year":"2017","unstructured":"Schlafer D, Shah KS, Panjic EH, Lonial S (2017) Safety of proteasome inhibitors for treatment of multiple myeloma. Expert Opin Drug Saf 16(2):167\u2013183","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"863_CR79","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/gut.2009.203554","volume":"59","author":"N Schmidt","year":"2010","unstructured":"Schmidt N, Gonzalez E, Visekruna A, K\u00fchl AA, Loddenkemper C, Mollenkopf H et al (2010) Targeting the proteasome: partial inhibition of the proteasome by bortezomib or deletion of the immunosubunit LMP7 attenuates experimental colitis. Gut 59(7):896\u2013906","journal-title":"Gut"},{"issue":"10","key":"863_CR80","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1177\/1756285617721093","volume":"10","author":"C Schneider-Gold","year":"2017","unstructured":"Schneider-Gold C, Reinacher-Schick A, Ellrichmann G, Gold R (2017) Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience. Ther Adv Neurol Disord 10(10):339\u2013341","journal-title":"Ther Adv Neurol Disord"},{"issue":"2","key":"863_CR81","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1177\/0961203319896018","volume":"29","author":"A Segarra","year":"2020","unstructured":"Segarra A, Arredondo KV, Jaramillo J, Jatem E, Salcedo MT, Agraz I et al (2020) Efficacy and safety of bortezomib in refractory lupus nephritis: a single-center experience. Lupus 29(2):118\u2013125","journal-title":"Lupus"},{"issue":"4","key":"863_CR82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cell.2010.07.036","volume":"142","author":"U Seifert","year":"2010","unstructured":"Seifert U, Bialy LP, Ebstein F, Bech-Otschir D, Voigt A, Schr\u00f6ter F et al (2010) Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell 142(4):613\u2013624","journal-title":"Cell"},{"key":"863_CR83","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1196\/annals.1254.026","volume":"998","author":"H Shiono","year":"2003","unstructured":"Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW et al (2003) Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann N Y Acad Sci 998:237\u2013256","journal-title":"Ann N Y Acad Sci"},{"key":"863_CR84","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1056\/NEJMc1213206","volume":"369","author":"J Shortt","year":"2013","unstructured":"Shortt J, Oh DH, Opat SS (2013) ADAMTS13 antibody depletion by bortezomib in thrombotic thrombocytopenic purpura. N Engl J Med (united States) 369:90\u201392","journal-title":"N Engl J Med (united States)"},{"issue":"21","key":"863_CR85","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1073\/pnas.0401563101","volume":"101","author":"K Sun","year":"2004","unstructured":"Sun K, Welniak LA, Panoskaltsis-Mortari A, O\u2019Shaughnessy MJ, Liu H, Barao I et al (2004) Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 101(21):8120\u20138125","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5","key":"863_CR86","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/ar2309","volume":"9","author":"YKO Teng","year":"2007","unstructured":"Teng YKO, Verburg RJ, Verpoort KN, Diepenhorst GMP, Bajema IM, van Tol MJD et al (2007) Differential responsiveness to immunoablative therapy in refractory rheumatoid arthritis is associated with level and avidity of anti-cyclic citrullinated protein autoantibodies: a case study. Arthritis Res Ther 9(5):R106","journal-title":"Arthritis Res Ther"},{"key":"863_CR87","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/S0065-2776(08)60342-9","volume":"37","author":"AN Theofilopoulos","year":"1985","unstructured":"Theofilopoulos AN, Dixon FJ (1985) Murine models of systemic lupus erythematosus. Adv Immunol 37:269\u2013390","journal-title":"Adv Immunol"},{"key":"863_CR88","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1124\/pr.117.015370","volume":"71","author":"TA Thibaudeau","year":"2019","unstructured":"Thibaudeau TA, Smith DM (2019) A Practical review of proteasome pharmacology. Pharmacol Rev 71:170\u2013197","journal-title":"Pharmacol Rev"},{"issue":"3","key":"863_CR89","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nri2727","volume":"10","author":"K Tokoyoda","year":"2010","unstructured":"Tokoyoda K, Hauser AE, Nakayama T, Radbruch A (2010) Organization of immunological memory by bone marrow stroma. Nat Rev Immunol [internet] 10(3):193\u2013200. https:\/\/doi.org\/10.1038\/nri2727","journal-title":"Nat Rev Immunol [internet]"},{"issue":"1","key":"863_CR90","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/ejh.12206","volume":"92","author":"T van Balen","year":"2014","unstructured":"van Balen T, Schreuder MF, de Jong H, van de Kar NCAJ (2014) Refractory thrombotic thrombocytopenic purpura in a 16-year-old girl: successful treatment with bortezomib. Eur J Haematol 92(1):80\u201382","journal-title":"Eur J Haematol"},{"issue":"10","key":"863_CR91","doi-asserted-by":"publisher","first-page":"2734","DOI":"10.1093\/rheumatology\/kez623","volume":"59","author":"LS van Dam","year":"2020","unstructured":"van Dam LS, Osmani Z, Kamerling SWA, Kraaij T, Bakker JA, Scherer HU et al (2020) A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE. Rheumatology (oxford) 59(10):2734\u20132745","journal-title":"Rheumatology (oxford)"},{"issue":"1","key":"863_CR92","first-page":"92","volume":"27","author":"JW van der Heijden","year":"2009","unstructured":"van der Heijden JW, Oerlemans R, Lems WF, Scheper RJ, Dijkmans BAC, Jansen G (2009) The proteasome inhibitor bortezomib inhibits the release of NFkappaB-inducible cytokines and induces apoptosis of activated T cells from rheumatoid arthritis patients. Clin Exp Rheumatol 27(1):92\u201398","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"863_CR93","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1006\/jaut.2000.0370","volume":"14","author":"CL Vanderlugt","year":"2000","unstructured":"Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD (2000) Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 14(3):205\u2013211","journal-title":"J Autoimmun"},{"issue":"1","key":"863_CR94","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-015-0529-1","volume":"17","author":"SE Verbrugge","year":"2015","unstructured":"Verbrugge SE, Scheper RJ, Lems WF, de Gruijl TD, Jansen G (2015) Proteasome inhibitors as experimental therapeutics of autoimmune diseases. Arthritis Res Ther 17(1):17","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"863_CR95","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/s41590-018-0130-2","volume":"19","author":"EF Verdu","year":"2018","unstructured":"Verdu EF, Danska JS (2018) Common ground: shared risk factors for type 1 diabetes and celiac disease. Nat Immunol 19(7):685\u2013695","journal-title":"Nat Immunol"},{"key":"863_CR96","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/1752-1947-8-19","volume":"8","author":"N Vinayek","year":"2014","unstructured":"Vinayek N, Sharma V (2014) A combination of bortezomib and rituximab yields a dramatic response in a woman with highly refractory immune thrombocytopenic purpura: a case report. J Med Case Rep 8:19","journal-title":"J Med Case Rep"},{"issue":"5\u20136","key":"863_CR97","doi-asserted-by":"publisher","first-page":"380","DOI":"10.3109\/08916930903518073","volume":"43","author":"K Vrolix","year":"2010","unstructured":"Vrolix K, Fraussen J, Molenaar PC, Losen M, Somers V, Stinissen P et al (2010) The auto-antigen repertoire in myasthenia gravis. Autoimmunity 43(5\u20136):380\u2013400","journal-title":"Autoimmunity"},{"issue":"9894","key":"863_CR98","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","volume":"382","author":"M Wahren-Herlenius","year":"2013","unstructured":"Wahren-Herlenius M, D\u00f6rner T (2013) Immunopathogenic mechanisms of systemic autoimmune disease. Lancet (london, England) 382(9894):819\u2013831","journal-title":"Lancet (london, England)"},{"issue":"4","key":"863_CR99","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/joim.12395","volume":"278","author":"L Wang","year":"2015","unstructured":"Wang L, Wang F-S, Gershwin ME (2015a) Human autoimmune diseases: a comprehensive update. J Intern Med 278(4):369\u2013395","journal-title":"J Intern Med"},{"key":"863_CR100","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1093\/rheumatology\/keu393","volume":"54","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhou W, Zhang Z (2015b) Successful treatment of warm-type haemolytic anaemia with bortezomib in a rituximab-failed systemic lupus erythematosus patient. Rheumatology (oxford) 54:194\u2013195","journal-title":"Rheumatology (oxford)"},{"issue":"11","key":"863_CR101","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1038\/cmi.2017.8","volume":"14","author":"F Xiao","year":"2017","unstructured":"Xiao F, Lin X, Tian J, Wang X, Chen Q, Rui K et al (2017) Proteasome inhibition suppresses Th17 cell generation and ameliorates autoimmune development in experimental Sj\u00f6gren\u2019s syndrome. Cell Mol Immunol 14(11):924\u2013934","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"863_CR102","doi-asserted-by":"publisher","first-page":"e34587","DOI":"10.1371\/journal.pone.0034587","volume":"7","author":"K Yanaba","year":"2012","unstructured":"Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S (2012) Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. PLoS ONE 7(3):e34587","journal-title":"PLoS ONE"},{"issue":"11","key":"863_CR103","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1002\/art.27690","volume":"62","author":"E Yannaki","year":"2010","unstructured":"Yannaki E, Papadopoulou A, Athanasiou E, Kaloyannidis P, Paraskeva A, Bougiouklis D et al (2010) The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheumatol 62(11):3277\u20133288","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"863_CR104","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1111\/trf.12614","volume":"54","author":"S Yates","year":"2014","unstructured":"Yates S, Matevosyan K, Rutherford C, Shen Y-M, Sarode R (2014) Bortezomib for chronic relapsing thrombotic thrombocytopenic purpura: a case report. Transfusion 54(8):2064\u20132067","journal-title":"Transfusion"},{"issue":"8","key":"863_CR190","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1001\/jamaneurol.2017.1336","volume":"74","author":"C Zhang","year":"2017","unstructured":"Zhang C, Tian D-C, Yang C-S, Han B, Wang J, Yang L et al (2017) Safety and efficacy of bortezomib in patients with highly relapsing neuromyelitis optica spectrum disorder. JAMA Neurol 74(8):1010\u20131012","journal-title":"JAMA Neurol"},{"issue":"9\u201310","key":"863_CR197","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.imbio.2009.06.018","volume":"214","author":"E Zinser","year":"2009","unstructured":"Zinser E, R\u00f6ssner S, Littmann L, L\u00fcftenegger D, Schubert U, Steinkasserer A (2009) Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 214(9\u201310):843\u2013851","journal-title":"Immunobiology"},{"issue":"5","key":"863_CR191","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1172\/JCI0212736","volume":"109","author":"TM Zollner","year":"2002","unstructured":"Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke W-H (2002) Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Investig 109(5):671\u2013679","journal-title":"J Clin Investig"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-021-00863-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-021-00863-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T22:02:02Z","timestamp":1673128922000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-021-00863-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,23]]},"references-count":110,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["863"],"URL":"https:\/\/doi.org\/10.1007\/s10787-021-00863-2","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,23]]},"assertion":[{"value":"29 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}